DDInter1442 DDInter899
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Phenobarbital {u} (Compound) resembles {v} (Compound) Primidone
Phenobarbital {u} (Compound) resembles {v} (Compound) Methsuximide
Phenobarbital {u} (Compound) treats {v} (Disease) epilepsy syndrome
Phenobarbital {u} (Compound) binds {v} (Gene) ABCC3
Phenobarbital {u} (Compound) causes {v} (Side Effect) Mental disability
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Sunitinib
Phenobarbital (Compound) resembles Primidone (Compound)
Phenobarbital (Compound) resembles Methsuximide (Compound)
Phenobarbital (Compound) treats epilepsy syndrome (Disease)
Phenobarbital (Compound) binds ABCC3 (Gene)
Phenobarbital (Compound) causes Mental disability (Side Effect)
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Phenobarbital may lead to a major life threatening interaction when taken with Sunitinib